Merck, AstraZeneca amend long-standing partnership
10:36 EDT 27 Jun 2012 | Advantage Business Media
Drugmakers Merck & Co. and AstraZeneca PLC have amended their U.S. partnership to give AstraZeneca a 2014 buyout option that could cost more than $400 million.The companies said Wednesday that London-based AstraZeneca will have an option to purchase..
Original Article: Merck, AstraZeneca amend long-standing partnership
More From BioPortfolio on "Merck, AstraZeneca amend long-standing partnership"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
